Table 7.

Clinical trials of natural products to treat heart-related diseases (https://clinicaltrials.gov).

Compound	ClinicalTrials.gov Identifier	Type of study	Characteristics of patients (n)	Dose and time of treatment	Condition	Phase	Additional Refs
Fucoxanthin and oligo fucoidan	NCT02875392	randomized, Interventional, placebo-controlled trial	FuciHiQ group (n = 21) or placebo group (n = 21)	FucoHiQ (275 mg Oligo Fucoidan + 275 mg HS Fucoxanthin) 550mg/capsule 6 per day	non-alcoholic Fatty Liver Disease	–	[100]
Xanthohumol	NCT01367431	Observational	20 mg group, 60 mg group and 180 mg group; n = 48	one capsule of one of the three doses (20, 60, 180 mg) randomly assigned	heart disease	–
Cocoa polyphenols	NCT00654862	randomized, Interventional, placebo-controlled trial	250 mg group, 1000 mg group, placebo; n = 48	oral administration of capsules with 1000 or 250 mg polyphenols	hypertension	phase 1
Catechin epigallocatechin-3-gallate (EGCG)	NCT01662232	randomized, Interventional, placebo-controlled trial	200 mg group, placebo group; n = 50	200 mg EGCG	cardiovascular diseases	–
Exenatide	NCT00650546	Open label	N = 8	5 mcg twice a day titrated to 10 mcg twice a day	nonalcoholic fatty liver disease	phase 2/3